Source link : https://www.newshealth.biz/health-news/gene-therapy-details-revealed-in-duchenne-trial/
SAVANNAH, Ga. — Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences emerged in other functional outcomes, the phase III EMBARK trial showed. The primary outcome was the change from baseline in North Star Ambulatory Assessment (NSAA) scores at 1 year. The NSAA measures 17 motor […]
Author : News Health
Publish date : 2024-10-18 14:55:57
Copyright for syndicated content belongs to the linked Source.
Categories